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Abstract
Background & aims: Inflammation is a hallmark of cancer, yet the mechanisms that regulate immune cell infiltration
into tumors remain poorly characterized. This study attempted to characterize the composition, distribution,
and prognostic value of CXCR2+ cells in hepatocellular carcinoma (HCC) and to examine the CXCR2 ligands
that are responsible for local immune infiltration in different areas of HCC tumors.
Methods: Immunohistochemistry and immunofluorescene were used to identify CXCR2+ cells in HCC tissues.
Kaplan–Meier analysis and Cox regression models were applied to estimate recurrence-free survival (RFS) and overall
survival (OS) for 259 HCC patients. The expression levels of CXCR2 ligands (CXCL-1, −2, −5, and −8) were measured by
real-time PCR and compared with local immune cell density. The combined prognostic value of the CXCR2–CXCL1 axis
was further evaluated.
Results: In HCC tissues, CXCR2+ cells were mainly neutrophils that were enriched in the peri-tumoral stroma (PS)
region. Kaplan–Meier survival analysis showed that increased CXCR2+PS cells were associated with reduced RFS and OS
(P = 0.015 for RFS; P = 0.002 for OS). Multivariate Cox proportional hazards analysis identified CXCR2+PS cell density as an
independent prognostic factor for OS (hazard ratio [HR] = 1.737, 95 % confidence interval [CI] = 1.167–2.585, P = 0.006).
Furthermore, we detected a positive correlation between the density of CD15+ neutrophils and CXCL1 levels in both
the peri-tumoral stroma and intra-tumoral regions. The combination of CXCR2 and CXCL1 expression levels represented a
powerful predictor of a poor prognosis for patients with HCC.
Conclusions: Our data showed that the CXCR2+ cell density was an independent prognostic factor for predicting OS for
HCC patients. The CXCR2–CXCL1 axis can regulate neutrophil infiltration into HCC tumor tissues and might represent a
useful target for anti-HCC therapies.
Keywords: Hepatocellular carcinoma, Chemokine, CXCR2, CXCL1, Immune cell infiltration, Prognosis
Background
Hepatocellular carcinoma (HCC) is an aggressive malig-
nancy with an increasing rate of incidence and a poor
prognosis [1]. Surgical intervention represents the most
effective therapy for HCC; however, more than 70 % of
patients relapse within 5 years, and overall survival
remains poor [2]. Although several types of adjuvant ther-
apy have been reported to reduce the recurrence rate, the
benefits of these approaches are limited [3]. Thus, an ur-
gent unmet need exists to gain a better understanding of
the underlying mechanisms that lead to tumor progression
and to identify prognostic biomarkers for HCC patients.
HCCs are typically attributed to chronic hepatitis B or C
viral infections and, thus, present with extensive immune
cell infiltration [4, 5]. A growing number of studies indicate
that immune cells in different tumor milieus can exhibit
diverse functions in that regulate tumor growth, invasion,
and angiogenesis [6–9]. Our previous studies have shown
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that activated monocytes in peri-tumoral regions can
attenuate T cell responses by expressing PD-L1, whereas
suppressive macrophages in a tumor nest can induce the
generation of regulatory T (Treg) cells to promote tumor
progression [10–12]. We also found that neutrophils accu-
mulated in the peri-tumoral regions of HCC where they
promoted angiogenesis by releasing MMP9 [13]. Accord-
ingly, the density of macrophages and neutrophils were
both correlated with patient prognoses in HCC. However, it
remains unclear how these diverse types of immune cells
can be selectivity recruited to different tumor sites.
Chemokines are low molecular weight (8 to 14 kDa)
chemotactic cytokines with diverse bioactivities that can
mediate the recruitment and trafficking of leukocytes to
tumor microenvironments [14]. Different tumors exhibit
distinct chemokine expression profiles, which can lead
to diverse immune cell infiltration and clinical outcomes.
CXC receptor 2 (CXCR2) is a member of the G-protein-
coupled receptor superfamily. Previous studies have
revealed that CXCR2 and its ligands (CXCL-1, −2, −3,
−5, −6, −7, and −8) are involved in tumor angiogenesis,
tumorigenesis, and metastasis of several types of human
cancers, such as colorectal carcinoma, melanoma, lung
cancer, renal cell carcinoma, prostate carcinoma, pancre-
atic carcinoma, and esophageal carcinoma [15–21].
CXCR2 expression has been detected on monocytes,
macrophages, lymphocytes, neutrophils, mast cells, and
endothelial cells [14, 22]. However, the composition
and distribution of CXCR2+ cells, and the role of these
cells in immune modulation in HCC has been not been
well characterized.
Herein, we investigate the expression and prognostic
significance of CXCR2 expression in HCC patients. We
also explore the possible involvement of CXCR2 and its
ligands in regulating immune cell infiltration into HCC
tissues. Our findings show that the CXCR2–CXCL1 axis
is correlated with CD15+ neutrophil infiltration into
both intra- and peri-tumoral regions, and represents an
independent prognostic factor in HCC.
Materials and methods
Patients and specimens
Archived, formalin-fixed, paraffin-embedded tissues
from 259 patients (Group 1) who had all undergone
curative resection for HCC at the Sun Yat-Sen University
Cancer Center between 2007 and 2010 were enrolled in
this prognostic study. Patients who exhibited signs of
distant metastasis, had received anti-cancer therapies
prior to surgery, or experienced concurrent autoimmune
disease were excluded. The diagnosis of HCC in each
patient was confirmed histopathologically. Curative
resection for HCC was defined as complete resection of
all tumor nodules with a resection margin of at least 1 cm,
and with a cut surface that was free of tumors based on
histological examinations. To ensure the complete removal
of HCC, intraoperative ultrasound and postsurgical
contrast-enhanced computed tomography (CT) were
routinely used [13, 23, 24]. The tumor stage was deter-
mined according to the Barcelona-Clinic Liver Cancer
(BCLC) staging classification and tumor-node-metastasis
(TNM) classification system of the International Union
Against Cancer, 7th Edition [25]. Tumor differentiation
was graded according to the Edmondson grading system.
Liver function was assessed based on the Child–Pugh
scoring system. Data was censored at the last follow-up for
patients without recurrence or death. Recurrence-free
survival (RFS) was defined as the time from the date of
surgery to either recurrence, the last follow-up, or death if
no recurrence was observed. Overall survival (OS) was
defined as the interval between the time of surgery to
either the last follow-up or death.
Frozen and matched formalin-fixed, paraffin-embedded
tissues from 30 HCC patients (Group 2) who received
therapy between 2012 and 2013 were used for real-time
PCR and tissue microarray (TMA) analyses, respectively.
This study strictly conformed to the ethical guidelines
of the Declaration of Helsinki and was approved by the
Research Ethics Committee of Sun Yat-Sen University
Cancer Center. Written informed consent was obtained
from all patients prior to sample collection. All samples
were coded and data was stored anonymously. The
clinicopathological characteristics of all patients are
summarized in Table 1.
Tissue microarray and immunohistochemistry
Immunohistochemistry (IHC) for detecting CXCR2 and
CXCL1 was carried out on paraffin-embedded sections
from 259 patients. IHC for CD3, CD15, S100, and
CD68 was performed on TMA sections that contained
30 specimens.
The TMA was constructed as described previously
[23, 24]. Briefly, each representative area was premarked
in the paraffin-embedded blocks by hematoxylin and eosin
(H&E) staining, excluding necrotic and hemorrhagic areas.
To ensure reproducibility and homogeneity, duplicates
of 2 mm (diameter) cylinders from the peri-tumoral
stroma region, and 1 mm (diameter) cylinders from the
intra-tumoral and non-tumor regions were obtained
from each patient.
IHC was performed using a two-step protocol
(DakoCytomation, Glostrup, Denmark) using proto-
cols described in our previous studies [23, 24]. Sections of
formalin-fixed, paraffin-embedded tissues were cut using
a microtome, and then were sequentially dried, dewaxed,
and re-hydrated with xylene and a decreasing ethanol
series. Next, endogenous peroxidase activity was blocked
with 0.3 % H2O2 for 10 min. For antigen retrieval, sections
were steamed in 10 mM citrate buffer (pH 6.0) for
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10 min. Glass slides were incubated overnight at 4 °C with
anti-CXCR2 (Monoclonal Mouse IgG2A; Clone 48311;
R&D Systems, Minneapolis, MN, USA), anti-CXCL1
(Polyclonal Rabbit Antibody, LifeSpan BioSiences, Seattle,
WA, USA), anti-CD3 (Monoclonal Rabbit IgG; Clone
SP7, Thermo Scientific, Waltham, MA, USA), anti-CD15
(Monoclonal Mouse IgM; Clone LeuM1; Beijing
Zhongshan Golden Bridge Biotechnology, Beijing, China),
anti-S100 (Monoclonal Mouse IgG2A; Clone 4C4.9;
Thermo Scientific), or anti-CD68 (Monoclonal Mouse
IgG3; Clone PG-M1; DakoCytomation, Carpinteria, CA,
USA) antibodies. Horseradish peroxidase-conjugated
anti-rabbit and anti-mouse Dako EnVision systems
(DakoCytomation) were used as secondary detection
reagents that were developed using 3,3′-diaminobenzidine
(DAB). All sections were lightly counterstained with
Mayer’s Hematoxylin Solution (Sigma) and mounted using
non-aqueous Permount TM mounting medium. Negative
controls were slides for which the primary antibodies were
replaced by the same concentration of an irrelevant,
isotype-matched antibody. Brown precipitate indicated
positive immunoreactivity.
Immunofluorescent staining
For double-immunofluorescence of CD3, CD15, CD68, or
S100 along with CXCR2, a fluorescein tyramide signal
amplification (TSA) system (TSA-Plus Fluorescence
Palette System, PerkinElmer) was used according to the
manufacturer’s instructions. Fluorescent signals were pro-
duced using Cy3, fluorescein, or Cy5 TSA systems. Nuclei
were counterstained using DAPI.
Automated image acquisition and quantification
To quantify CXCR2 expression, the Vectra-Inform
image analysis system (Perkin-Elmer/Applied Biosys-
tems, Foster City, CA, USA) was used as described in
previous studies [24]. Briefly, slides were loaded onto a
Vectra slide scanner following the manufacturer’s
protocol. Representative areas for tissues from each pa-
tient were collected in 10–12 fields from each slide at a
constant 200× magnification. Stained slides were imaged
using a Nuance VIS-FL Multispectral Imaging System
(Perkin-Elmer/Applied Biosystems). The spectrum for
each chromogen was determined on single-stained control
slides. A spectral un-mixing algorithm separated grayscale
images that quantitatively captured each spectral compo-
nent. Images were analyzed with InForm 2.0.1 image ana-
lysis software (Perkin-Elmer Applied Biosystems).
For staining with DAB and hematoxylin, a standard
bright field scanning protocol was developed. Using
InForm software, the tissue (blank, tumor tissue, peri-
tumoral stroma tissue) and cell (nucleus, cytoplasm)
compartments could be segregated [24]. Target signals
were quantified in selected tissues and cellular compart-
ments of interest. For a given area of tissue, the category
area (percentage), number of cells, positivity, and DAB
object density counts per megapixel were used in subse-
quent analyses. The percentage of each immune cell
subset (CD3, CD15, and CD68) was calculated by divid-
ing the absolute number of each cell subset by the total
number of infiltrating immune cells.
To quantify immunofluorescence, a standard
fluorescence-field scanning protocol was developed. Pro-
portions of cells in different populations were calculated
[e.g., the proportion of CXCR2+ cells that were CD15+
neutrophils would be calculated as: (number of CXCR2
+CD15+ cells) / (number of CD15+CXCR2+ cells + CD15
−CXCR2+ cells].
Real-time quantitative RT-PCR and gene expression
analysis
Total RNA was extracted from HCC tumor samples and
corresponding peri-tumoral and non-tumoral liver tissues
using TRIzol reagent (Invitrogen) according to the manu-
facturer’s instructions. Equal concentrations of total RNA
were used in reverse transcription reactions to generate
cDNA using a miScript Reverse Transcription Kit (Qiagen,
Hilden, Gemany), then each cDNA was used in SYBR
Green real-time quantitative PCR according to standard
protocols; primer sequences are listed in Additional file 1:
Table S1. All real-time quantitative PCR was performed on
a Roche LightCycler480 (Roche Diagnostics). Data were
generated using LightCycler480 software (version 1.5.0).
Levels of target genes were normalized to levels of the
expression of a reference gene, GAPDH. Data were proc-
essed using GraphPad Prism software (La Jolla, CA, USA).
Table 1 Clinical characteristics of patients with HCC
Variables Group 1 Group 2
Cases (n) 259 30
Age, years (median, range) 52, 13–79 42,26–80
Gender (male / female) 226/33 29/1
HBsAg (negative / positive) 20/239 1/29
Cirrhosis (absent / present) 96/163 6/24
ALT (U/liter, ≤42 / >42) 154/105 16/14
AST (U/liter, ≤42 / >42) 150/109 18/12
AFP (ng/ml, ≤25 / >25) 89/170 11/19
Tumor size (cm, ≤5 / >5) 109/150 12/18
Tumor differentiation (I–II / III–IV) 133/124 16/14
Vascular invasion (absent / present) 210/49 18/12
Tumor multiplicity (solitary / multiple) 194/65 17/13
TNM stage (I–II / III–IV) 139/120 22/8
BCLC stage (0–A vs. B–C) 152/107 10/20
Abbreviations: AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate
aminotransferase, BCLC Barcelona Clinic Liver Cancer, HBsAg hepatitis B surface
antigen, TMA tissue microarray, TNM tumor-nodes-metastasis
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Statistical analyses
RFS and OS curves were obtained using the Kaplan–Meier
method, and compared using the log-rank test for each
prognostic variable. Variables with effects on survival in
univariate analysis were included in a multivariate Cox
proportional hazard regression model, which was used to
estimate the adjusted hazard ratio (HR) and 95 % confi-
dence interval (CI) and to identify independent prognostic
factors. Subgroups of each immunostaining parameter were
divided by median values. Associations between immuno-
staining parameters and clinicopathological features were
evaluated using the χ2 test or Fisher’s exact test as appropri-
ate. Associations between numbers of tumor-infiltrating
immune cells and the expression levels of CXCR2 ligands
were calculated using Pearson’s test. A threshold of P <0.05
was set to denote statistical significance. SPSS 17.0 (IBM)
was used for statistical analyses.
Results
CXCR2 expression in HCC tissues
To assess CXCR2 expression in HCC tumors, we per-
formed IHC staining in paraffin-embedded sections.
CXCR2 signals were mainly identified in the cytoplasm of
stromal cells (Fig. 1a). CXCR2+ cells were dispersed and
found to be enriched in peri-tumoral stroma (PS) com-
pared with non-tumoral (NT) or intra-tumoral (IT)
regions, with mean (± SEM) densities of 12.61 ± 0.61, 9.39
± 0.39, and 7.98 ± 0.40, respectively (Fig. 1b).
Multiple immunofluorescence staining for CXCR2 and
various immune cell markers (CD15, neutrophils; CD68,
macrophages; CD3, T cells; S100, dendritic cells) was
performed (Fig. 1c), and then images were analyzed
using the Vectra-Inform image analysis system to calcu-
late the proportion of CXCR2+ cells within each cellular
subset in HCC tissues. As shown in Fig. 1, most CXCR2
+ cells were CD15+ neutrophils in the NT, PS, and IT
regions of HCC tissues (49.6 % ± 2.1 %, 64.0 % ± 3.4 %,
and 28.7 % ± 2.6 %, respectively; n = 30; Fig. 1e), whereas
only a small portion of CXCR2+ cells were CD68+
macrophages (11.1 % ± 1.1 %, 14.4 % ± 1.2 %, and 18.7 %
± 1.0 %, respectively), CD3+ T cells (26.1 % ± 2.1 %,
14.1 % ± 1.2 %, and 13.2 % ± 0.9 %), or S100+ dendritic
cells (2.4 % ± 0.4 %, 1.2 % ± 0.2 %, and 1.3 % ± 0.2 %).
Moreover, the proportion of CD15+ neutrophils that
expressed CXCR2 in the NT, PS, and IT regions was
55.2 % ± 2.0 %, 78.6 % ± 2.9 %, and 48.9 % ± 1.8 %,
respectively (Fig. 1d).
Increased CXCR2+ cells predicted poor survival
The relationship between CXCR2+ cells and patient
survival was further investigated. A cohort of 259 HCC
patients who had received curative resection were divided
into two groups based on the median value of CXCR2+
cell density in NT (CXCR2+NT cells; median density, 10.87),
PS (CXCR2+PS cells; median density, 12.45) and IT
(CXCR2+IT cells; median density, 8.22) areas. Kaplan–Meier
survival analysis revealed a negative association between
the density of CXCR2+PS cells and the RFS and OS of
patients (P = 0.015 for RFS, P = 0.002 for OS; log-rank test;
Fig. 2). An increased density of CXCR2+PS cells was asso-
ciated with a shorter RFS (median, 15 months) and OS
(median, 45 months) compared with patients exhibiting
a low CXCR2+PS cell density (median, 32 months and
>72 months, respectively). In patients with a high dens-
ity of CXCR2+PS cells, the 5-year RFS and OS rates were
only 27.7 and 40.7 %, compared with 40.8 and 63.4 % in
patients with a low CXCR2+PS cell density, respectively.
However, no association was observed for CXCR2+ cells
in the NT or IT regions (Fig. 2).
To assess whether CXCR2 could be used as an inde-
pendent predictor of survival, we performed multivariate
Cox proportional hazards analysis. CXCR2+PS cell density
was associated with an elevated risk of recurrence
(HR = 1.358, 95 % CI = 0.989–1.866, P = 0.059) and
death (HR = 1.737, 95 % CI = 1.167–2.585, P = 0.006).
Clinicopathological variables that were shown to be
significant in the univariate analysis were used as co-
variates in the multivariate analysis, and the CXCR2+PS
cell density was found to be an independent prognos-
tic factor for OS (Table 2). In addition to CXCR2, the
multivariate Cox proportional hazards analysis showed
that serum AFP levels also represented an independ-
ent predictor of OS (P = 0.029).
We also tested whether there were any significant
associations between the CXCR2 density and clinico-
pathological variables. The density of CXCR2+ cells was
significantly increased in HCC patients with less-
differentiated NT, PS, and IT regions (P = 0.015, P = 0.040,
and P = 0.040, respectively; Additional file 2: Table S2).
Associations between CXCR2 ligand expression and local
immune cell infiltration
To further assess the expression of CXCR2 ligands in
HCC, we analyzed the mRNA transcript levels of CXCL-1,
−2, −5, and −8 in 30 HCC tumor samples with matched
peri-tumoral and non-tumorous liver tissues (Additional
file 3: Figure S1), We also examined local immune cell
infiltration in the same samples by IHC staining for CD3,
CD15, and CD68. Consistent with our previous findings,
CD15+ cells and CD3+ T cells (Additional file 4: Figure S2)
were predominantly enriched in the PS region surround-
ing the tumor nest at the tumor edge [13, 23]. Correla-
tions between CXCL-1, −2, −5, and −8 expression and the
density of CD3+, CD15+, and CD68+ cells in HCC tissues
were examined using Pearson’s correlation test. We de-
tected a positive correlation between the density of CD68+
cells and CXCL8 expression (R = 0.465; P = 0.011; Fig. 3)
and a positive correlation between the density of CD15+
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cells and CXCL1 and CXCL2 expression (R = 0.376,
P = 0.040; and R = 0.517, P = 0.003, respectively; Fig. 3)
in the IT region. However, in the PS region, the
density of CD15+ cells was only correlated with
CXCL1 expression (R = 0.391, P = 0.033; Fig. 3).
These findings indicated that the CXCL1–CXCR2
axis may play an important role in promoting CD15+
neutrophil accumulation in HCC tumors.
Combination of CXCL1 and CXCR2 exhibits improved
prognostic power for HCC
Our aforementioned findings indicated that the density
of CXCR2+ cells represented a valuable independent
factor for predicting the prognosis of HCC, and CXCL1
was a key ligand responsible for mediating neutrophil
infiltration into HCC tumor tissues. Therefore, we ana-
lyzed whether the combination of CXCR2 and CXCL1
represented a more powerful criteria for predicting
patient prognoses.
To determine the relationship between CXCL1 expres-
sion and patient survival, CXCL1 expression was also di-
vided by the median CXCL1 object density per megapixel
(median NT, PS and IT CXCL1: 292.2, 337.8, and 418.6,
respectively). In all three regions, patients in the
CXCR2lowCXCL1low group exhibited a better RFS (median
RFS: 37 months for NT, 50 months for PS, and 48 months
for IT) and OS (median OS > 72 months for NT, PS, and
IT) than those in the CXCR2highCXCL1high group (median
RFS: 9 months for NT, 13 months for PS, and 12 months
for IT; median OS: 32 months for NT, 35 months for PS,
and 51 months for IT; Fig. 4). In the multivariate
Cox analysis, a combination of CXCR2 and CXCL1 in
the PS region was associated with an elevated risk of
death (HR = 1.194, 95 % CI = 1.044–1.366; P = 0.010;
Additional file 5: Table S3). These findings suggested
that CXCR2 and CXCL1 represented a powerful pre-
dictor of shorter OS for patients with HCC.
Discussion
In this present study, we found that most CXCR2+ cells
in HCC tumors were neutrophils, and that CXCR2 rep-
resents an independent prognostic factor for HCC after
resection. Patients with fewer CXCR2+ cells within the
peri-tumoral stroma had a significantly prolonged RFS
(See figure on previous page.)
Fig. 1 In situ CXCR2 expression in HCC tumors. a Representative images show CXCR2+ cells stained brown in non-tumor (NT), peri-tumoral stroma
(PS), and intra-tumor (IT) regions in HCC tissues. Black arrows indicate CXCR2+ cells. b The densities of CXCR2+ cells in the NT, PS, and IT regions
of HCC tissues were calculated (n= 259). Results are expressed as means ± SEM (bars) of each group. c Multiple stains for CD15, CD68, CD3, or S100 (red),
CXCR2 (green), and DAPI (blue) in paraffin-embedded sections were developed using a TSA system. White arrows indicate representative cells that express
CXCR2. d Vectra-Inform image analysis of the proportion of CXCR2+ cells among CD15+, CD68+, CD3+, or S100+ cells in HCC tissues (n= 30). Results are
expressed as means ± SEM (bars). e Proportions of CD15+, CD68+, CD3+, or S100+ cells among CXCR2+ cells in HCC tissues (n= 30). Results are expressed
as means ± SEM (bars); *, P<0.05; **, P<0.01; ***, P<0.001
Fig. 2 Accumulation of CXCR2+ cells predicts poor survival in HCC. OS (top) and RFS (bottom) were estimated using the Kaplan–Meier method
and compared using the log-rank test (n = 259)
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and OS compared with those patients with more CXCR2+
cells. Multivariate analysis showed that CXCR2 expression
in the peri-tumoral stroma could also serve as a useful
biomarker for predicting the prognosis of HCC. Further-
more, by analyzing associations between CXCR2 ligand
expression and immune cell infiltration, we found a
significant correlation between CXCL1 expression and
CD15+ neutrophil infiltration in both the PS and IT re-
gions. A combination of CXCR2 and CXCL1 expression
could improve the prognostic power for predicting sur-
vival. These findings suggest the possible involvement of
the CXCR2–CXCL1 axis in regulating neutrophil infiltra-
tion to promote HCC.
The chemokine network represents a unique group of
cytokines and receptors that exhibit various bioactivities
that can mediate the recruitment and trafficking of leu-
kocytes to tumor microenvironments. Various immune
cells can be recruited into tumors by diverse chemokines
[26]. Neutrophils represent an important component of
the intra-tumoral leukocyte infiltrate. Recent studies
have reported that both CXCR6 and CXCL5 are corre-
lated with intra-tumoral neutrophil infiltration in HCC
Table 2 Univariate and multivariate analyses of factors associated with survival and recurrence
OS RFS
Univariate Multivariate Univariate Multivariate
Variables P-value HR 95 % CI P-value P-value HR 95 % CI P-value
Age (>52 vs. ≤52 years) 0.438 NA 0.278 NA
Gender (male vs. female) 0.768 NA 0.407 NA
HBsAg (positive vs. negative) 0.372 NA 0.065 NA
Cirrhosis (present vs. absent) 0.278 NA 0.253 NA
ALT (>42 vs. ≤42 U/L) 0.206 NA 0.779 NA
AST (>42 vs. ≤42 U/L) 0.001 1.416 0.948–2.116 0.089 0.013 1.228 0.883–1.709 0.222
AFP (>25 vs. ≤25 ng/ml) 0.001 1.680 1.055–2.675 0.029 0.005 1.356 0.953–1.930 0.090
Tumor size (>5 vs. ≤5 cm) 0.002 1.134 0.702–1.832 0.609 0.016 1.018 0.694–1.493 0.929
Tumor differentiation (III–IV vs. I–II) 0.153 NA 0.377 NA
Vascular invasion (present vs. absent) <0.001 1.698 0.889–3.242 0.109 0.010 1.341 0.773–2.328 0.297
Tumor multiplicity (multiple vs. solitary) <0.001 1.276 0.664–2.452 0.464 <0.001 1.452 0.845–2.495 0.177
TNM stage (III–IV vs. I–II) <0.001 1.301 0.752–2.250 0.346 <0.001 1.300 0.835–2.024 0.246
BCLC stage (B–C vs. 0–A) <0.001 1.235 0.559–2.730 0.602 <0.001 1.061 0.558–2.020 0.856
CXCR2+NT cell (high vs. low) 0.060 NA 0.066 NA
CXCR2+PS cell (high vs. low) 0.002 1.737 1.167–2.585 0.006 0.018 1.358 0.989–1.866 0.059
CXCR2+IT cell (high vs. low) 0.169 NA 0.151 NA
Note: The Cox proportional hazards regression model was used. Variables used in multivariate analysis were adopted by univariate analysis. Terms in italics indicate
statistical significance
Abbreviations: AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, HBsAg hepatitis
B surface antigen, HR hazard ratio, NA not adopted, TNM tumor-nodes-metastasis
Fig. 3 Correlations between CXCL-1, −2, −5, and −8 expression and CD3+, CD15+, and CD68+ cell densities in HCC tissues. Correlation coefficients
between CXCL-1, −2, −5, and −8 expression and densities of each immune cell subset are shown; *, P <0.05; **, P <0.01
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[27, 28]. In this present study, we showed that compared
to HCC tissue and tumor-adjacent normal tissues, the
peri-tumoral stroma exhibited the highest density of
infiltrating CXCR2+ cells, which were mainly CD15+
neutrophils. By quantitative RT-PCR, we observed posi-
tive correlation of peri- and intra-tumoral CXCL1
expression with the density of CD15+ neutrophils. It has
been reported that CXCL1 can mediate neutrophil
migration in models of mouse lung inflammation and
experimental arthritis [29]. Together, our results indicate
that the CXCR2–CXCL1 axis is likely responsible for
regulating neutrophil inflation in HCC tumors, which
might further influence patient prognoses by facilitating
tumor angiogenesis [13].
Chemokines and chemokine receptors can affect mul-
tiple pathways that contribute to tumor progression.
Previous studies have reported roles for CXCR2 in tumor
development [30]. However, the functional roles of
CXCR2 in tumor cells remain the subject of debate.
CXCR2 has been shown to promote cell proliferation,
invasion, and migration, while CXCR2 inhibitors have
been reported to reduce tumor growth [31]. By contrast, a
recent study reported the induction of CXCR2 and
CXCR2 ligand expression by oncogenic K-ras, which rein-
forces senescence in vitro and suggests that it acts as a
tumor suppressor [32]. Chemokines can exert direct
effects on tumor cells and recruit various cell types to the
tumor microenvironment, which can further affect the
Fig. 4 Prognostic significance of the combined actions of CXCR2 and CXCL1 expression in association with RFS and OS. Kaplan–Meier curves illustrate the
duration of RFS and OS according to the combination of CXCR2 and CXCL1 expression in non-tumoral (a), peri-tumoral stroma (b) and intra-tumoral (c)
regions; *, P<0.05; **, P<0.01; ***, P<0.001
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immune status of a tumor. Herein, we examined the
expression of CXCR2 in HCC tissues, and found the
CXCR2 could indeed be expressed by different types of
immune cells, mainly neutrophils. The density of
CXCR2+ cells was inversely correlated with patient
prognoses. Therefore, we confirmed that CXCR2
expression on immune cells likely plays a vital role in
tumor progression.
The common ligands for CXCR2 are CXCL1, CXCL2,
CXCL5, and CXCL8. CXCL1 and CXCL2 are the main
ligands for CXCR2, which can mediate its roles in
metastasis and chemoresistance. Recent studies have
shown that CXCL1/2 can be hyperactivated in breast
cancer cell lines by chemotherapy and that blocking
CXCR2 in conjunction with chemotherapeutic agents
could markedly reduce lung metastases in xenograft-
implanted mice [33]. CXCL5 has been reported to be
up-regulated in malignant tumors, such as nasopharyn-
geal and colorectal cancer, and to be closely correlated
with a poor prognosis [27, 34–36]. In HCC, Zhou et al.
demonstrated that the CXCR2–CXCL5 axis can contrib-
ute to the EMT and HCC metastasis through activation of
PI3K/Akt/GSK-3β/Snail signaling [37]. CXCL8 expression
has been documented in infiltrating neutrophils, tumor-
associated macrophages, tumor cells, and endothelial cells,
and has been shown to regulate tumor angiogenesis,
tumor cell proliferation, and metastasis potential, such as
vessel invasion in HCC [38]. In this present study, we
found that CXCL8 was positively correlated with CD68
expression in the IT region, which indicated that CXCL8
might be responsible for macrophage recruitment into
tumor nests, which adds to the complexity of CXCR2-
mediated leukocyte recruitment to the HCC tumor
microenvironment.
Conclusions
Our study showed that most CXCR2+ cells are CD15+
neutrophils in HCC tissues. The CXCR2–CXCL1 axis
may be responsible for regulating neutrophil infiltration
in HCC and might represent a potential therapeutic
target for treating HCC.
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